Williams D L, Jones K L, Pettibone D J, Lis E V, Clineschmidt B V
Department of New Lead Pharmacology, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Biochem Biophys Res Commun. 1991 Mar 15;175(2):556-61. doi: 10.1016/0006-291x(91)91601-8.
In contrast to endothelin-1 (ET-1) and several of its analogues, sarafotoxin S6c (S6c) was a much more potent inhibitor of [125I]-ET-1 binding in rat hippocampus and cerebellum (Ki approximately 20 pM) than in rat atria and aorta (Ki approximately 4500 nM), suggesting the existence of ET-1 receptor subtypes (aorta/atria, ETA; hippocampus/cerebellum, ETB). S6c was a potent activator of PI turnover in hippocampus (EC50 approximately 10 nM) but not atria (EC50 greater than 1 microM), unlike ET-1 which was active in both tissues. S6c, therefore, is a highly selective ETB agonist. Furthermore, S6c was a potent pressor agent in the pithed rat (ED25 mm Hg approximately 0.1 nmoles/kg, i.v.), suggesting that the ETB receptor subtype may be important in cardiovascular function.
与内皮素 -1(ET -1)及其几种类似物相比,铃蟾毒素S6c(S6c)在大鼠海马体和小脑中对[125I]-ET -1结合的抑制作用(Ki约为20 pM)比在大鼠心房和主动脉中(Ki约为4500 nM)强得多,这表明存在ET -1受体亚型(主动脉/心房,ETA;海马体/小脑,ETB)。与在两种组织中均有活性的ET -1不同,S6c是海马体中磷脂酰肌醇(PI)周转的强效激活剂(EC50约为10 nM),但不是心房中的激活剂(EC50大于1 microM)。因此,S6c是一种高度选择性的ETB激动剂。此外,S6c在去脑大鼠中是一种强效升压剂(静脉注射时,ED25 mmHg约为0.1纳摩尔/千克),这表明ETB受体亚型可能在心血管功能中起重要作用。